Neobacimyx

This page contains information on Neobacimyx for veterinary use.
The information provided typically includes the following:
  • Neobacimyx Indications
  • Warnings and cautions for Neobacimyx
  • Direction and dosage information for Neobacimyx

Neobacimyx

This treatment applies to the following species:
Manufacturer: Intervet/Schering-Plough Animal Health

Product Information

(bacitracin-neomycin-polymyxin)

Ophthalmic Ointment

Sterile, Veterinary Antibacterial

NADA 65-016, Approved by FDA

Neobacimyx Caution federal Law Restricts This Drug To Use By Or On The Order Of A Licensed Veterinarian.

description Each Gram Contains: 400 Units Bacitracin Zinc, 5 Mg Neomycin Sulfate (equivalent To 3.5 Mg Neomycin Base), 10,000 Units Polymyxin B Sulfate, In A Base Of White Petrolatum And Mineral Oil.

actions The Three Antibiotics Present In Neobacimyx Ophthalmic Ointment Provide A Broad Spectrum Of Activity Against The Gram-positive And Gram-negative Bacteria Commonly Involved In Superficial Infections Of The Eyelid And Conjunctiva. Bacitracin Is Effective Against Gram-positive Bacteria Including Hemolytic And Non-hemolytic streptococci And staphylococci. Resistant Strains Rarely Develop. Neomycin Is Effective Against Both Gram-positive And Gram-negative Bacteria Including staphylococci, Escherichia Coli, And haemophilus Influenzae And Many Strains Of proteus And pseudomonas. Polymyxin B Is Bactericidal To Gram-negative Bacteria, Especially pseudomonas. No Resistant Strains Have Been Found To Develop in Vivo.

indications in The Treatment Of Superficial Bacterial Infections Of The Eyelid And Conjunctiva In Dogs And Cats When Due To Organisms Susceptible To The Antibiotics Contained In The Ointment. Laboratory Tests Should Be Conducted Including in Vitro Culturing And Susceptibility Tests On Samples Collected Prior To Treatment.

precautions Sensitivity To Neobacimyx Ophthalmic Ointment Is Rare, However, If A Reaction Occurs, Discontinue Use Of The Preparation. As With Any Antibiotic Preparation, Prolonged Use May Result In The Overgrowth Of Nonsusceptible Organisms Including Fungi. Appropriate Measures Should Be Taken If This Occurs. If Infection Does Not Respond To Treatment In 2 Or 3 Days, The Diagnosis And Therapy Should Be Reevaluated.

care Should Be Taken Not To Contaminate The Applicator Tip Of The Tube During Application Of The Preparation. Do Not Allow The Applicator Tip To Come In Contact With Any Tissue.

adverse Reactions Itching, Burning, Or Inflammation May Occur In Animals Sensitive To The Product. Discontinue Use In Such Cases.

dosage And Administration apply A Thin Film Over The Cornea Three Or Four Times Daily In Dogs And Cats. The Area Should Be Properly Cleansed Prior To The Use Of Neobacimyx Ophthalmic Ointment. Foreign Bodies, Crusted Exudates, And Debris Should Be Carefully Removed.

warning Do Not Use This Product As A Pre-surgical Ocular Lubricant. Adverse Reactions Of Ocular Irritation And Corneal Ulceration Have Been Reported In Association With Such Use.

How Supplied Neobacimyx Ophthalmic Ointment Is Available In Cartons Of 12 - 1/8 Oz (3.5 G) Sterile, Tamper-proof Tubes, Ndc 0061-0039-01.

store At 15° - 25°c (59° - 77°f).

Manufactured for Schering-Plough Animal Health Corporation, Summit, NJ 07901

by Nycomed US Inc., Melville, NY 11747

Copyright © 1985, 1990, 1998, Schering-Plough Animal Health Corp.

All rights reserved.

F-21342815

IF12838C SCHER

R11/07

#193

Nac No.

10471342

INTERVET/SCHERING-PLOUGH ANIMAL HEALTH
Distributed by INTERVET/SCHERING-PLOUGH ANIMAL HEALTH
29160 INTERVET LANE, P.O. BOX 318, MILLSBORO, DE, 19966-0318
Toll-Free:   800-992-8051
Customer Service:   800-441-8272
Website:   www.intervetusa.com
Email:   Information.USA@intervet.com
Every effort has been made to ensure the accuracy of the Neobacimyx information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-04-11

(web3)